Dietary Cholesterol and Adipose Tissue Inflammation
Withdrawn before enrolling · Not applicable
Conditions studied: Cholesterol
In brief
Hypothesis: increasing dietary cholesterol in humans will increase visceral, but not subcutaneous adipocyte size, free cholesterol content, and inflammatory gene expression. Visceral and abdominal subcutaneous adipose tissue biopsies will be obtained from non-obese subjects undergoing elective abdominal surgery at Wake Forest Baptist Medical Center after 3 weeks of zero (control) or 1g dietary cholesterol supplementation. Blood samples will also be taken before and after 3 weeks of dietary supplementation (0 vs. 1g dietary cholesterol) to measure plasma lipids levels, and ex vivo monocyte chemotaxis. Blood will also be used to isolate CD14+ monocytes for RNA extraction and storage for future transcriptome studies. Measurements of adipocyte size, free cholesterol content, and inflammatory gene and protein expression in the adipose tissue biopsies to test the hypothesis. Adipocytes and the stromal vascular fraction will be isolated and evaluated for CD14+ macrophages for RNA extraction and storage for future transcriptome analysis.
Key facts
- Study ID
- NCT03729141
- Run by
- Wake Forest University Health Sciences
- People needed
- 0
- Starts
- 2019-10-01
- Expected to finish
- 2019-12-01
- Last updated by the study team
- 2019-11-04
Who can join
Age: 18 and older, up to 70. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Age:18 to 70 years old
- Operated on by one of the study team surgeons at Wake Forest Baptist Medical Center.
You may not qualify if…
- History of liver disease (e.g., autoimmune hepatitis, Wilson's disease, hemochromatosis, 1 anti-trypsin deficiency), as determined by chart review
- Childs A, B, or C cirrhosis, as determined by chart review
- Present diagnosis/treatment of malignancy other than non-melanoma skin cancer
- Baseline INR > 1.8, as determined by chart review or need for continuous anticoagulation with warfarin or heparin
- Platelets <50,000 as determined by chart review
- Active immunomodulation therapy for chronic inflammatory diseases, including but not limited to rheumatoid arthritis, psoriasis, SLE, sarcoidosis, or inflammatory bowel disease
- Diabetes mellitus requiring treatment with oral agents or insulin
- Taking Questran, Colestid, or Zetia
- BMI over 30
Where it is running
- Wake Forest Baptist Medical Center — Winston-Salem, North Carolina, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.